SCHEMBL4101109

SCHEMBL4101109

Cc1ccccc1NC(=O)C1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
GAA P10253 3/20 0.56
MAPT P10636 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 2/20 0.54
P2RX7 Q99572 2/20 0.51
ABL1 P00519 1/20 0.51
RIN1 Q13671 1/20 0.51
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
EPHX2 P34913 1/20 0.50
USP30 Q70CQ3 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN6 P29350 1/20 0.49
MEN1 O00255 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3739365 0.88 PARP1 (0.53) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL762580 0.88 HDAC1 (0.62) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL17533942 0.88 HDAC1 (0.62) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL5871130 0.88 KMT2A (0.60) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL19378084 0.88 HDAC1 (0.62) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL25794128 0.87 PTPN2 (0.64) KMT2ATDP1ABL1RIN1EPHX2
SCHEMBL25362018 0.86 SIRT2 (0.51) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL30496077 0.86 SIRT2 (0.51) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL3715390 0.85 ABL1 (0.62) KMT2AGAAMAPTALDH1A1ABL1
SCHEMBL5870918 0.85 ABL1 (0.62) KMT2AGAAMAPTALDH1A1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-10-22 US disclosed
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-02-05 US disclosed
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP KMT2A 4610/4885GAA 3145/4885MAPT 1541/4885
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP KMT2A 4610/4885GAA 3145/4885MAPT 1541/4885
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP KMT2A 4610/4885GAA 3145/4885MAPT 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.